Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression

S. J. Kim1 · S. Garcia-Recio2 · C. J. Creighton3 · C. M. Perou2 · J. M. Rosen1

Received: 19 March 2018 / Revised: 20 March 2019 / Accepted: 14 April 2019
© The Author(s), under exclusive licence to Springer Nature Limited 2019

Abstract
Metastatic breast cancer is an extremely complex disease with limited treatment options due to the lack of information about the major characteristics of metastatic disease. There is an urgent need, therefore, to understand the changes in cellular complexity and dynamics that occur during metastatic progression. In the current study, we analyzed the cellular and molecular differences between primary tumors and paired lung metastases using a syngeneic p53-null mammary tumor model of basal-like breast cancer. Distinct subpopulations driven by the Wnt- and/or STAT3 signaling pathways were detected in vivo using a lentiviral Wnt- and STAT3 signaling reporter system. A significant increase in the overlapping populations driven by both the Wnt- and STAT3 signaling pathways was observed in the lung metastases as compared to the primary tumors. Furthermore, the overlapping populations showed a higher metastatic potential relative to the other populations and pharmacological inhibition of both signaling pathways was shown to markedly reduce the metastatic lesions in established lung metastases. An analysis of the unique molecular features of the lung metastases revealed a significant association with immune response signatures. Specifically, Foxp3 gene expression was markedly increased and elevated levels of Foxp3+ Treg cells were detected in close proximity to lung metastases. Collectively, these studies illustrate the importance of analyzing intratumoral heterogeneity, changes in population dynamics, and the immune microenvironment during metastatic progression.

Introduction
Metastasis accounts for the majority of cancer-related mortality and remains a major clinical obstacle for successful cancer management. In particular, triple-negative breast cancer (TNBC) metastasis tends to occur within the first 3 to 5 years after diagnosis, and TNBC patients have a shorter duration of overall survival and distant recurrence-free survival [1, 2]. Treatment decisions for patients with metastasis primarily rely on the biological characteristics of their primary tumors due to an incomplete understanding of factors driving metastatic disease. A better understanding of the molecular and cellular characteristics distinguishing primary tumors and metastases is crucial for developing the most appropriate therapeutic interventions to prevent and treat distant relapse.

Comparative genomic studies have shown that mutation patterns between primary tumors and metastases are similar with no consistent metastasis-specific mutations present other than pre-existing genetic alterations in primary tumors [3–8]. This close genetic relationship between primary tumors and metastases suggests that they are clonally related, and that metastases may arise from a subset of populations within primary tumors without having additional mutations. Growing evidence supports the existence of a unique population with metastasis-initiating ability, often referred to as metastasis-initiating cells (MICs), that might exist within the primary tumors or evolve throughout the metastatic progression [9]. Like tumor-initiating cells
(TICs), MICs possess stem cell-like properties and additionally exhibit cellular plasticity, which may contribute to tremendous clonal heterogeneity at sites of metastasis [10, 11]. In addition to stemness properties, MICs also have a unique capability to interact with distant organ microenvironments, critical for successful metastatic colonization [12]. The cellular origin of putative MICs and their clonal diversity are poorly understood.

Both normal and cancer stem cell-associated pathways appear to be critical nodes to support stemness and cellular plasticity during tumor progression and metastasis [13–15]. Wnt signaling is one of the fundamental pathways that function in both normal and cancer stem cells in multiple systems [16–19]. Hyperactivation of Wnt signaling and pathway components is frequently observed in basal-like TNBC [20–23]. Wnt-driven stemness has also been shown to be associated with increased metastatic capability and colonization in colorectal and breast cancers [15, 24]. Additionally, the signal transducer and activator of transcription 3 (STAT3) also represents a key modulator in cancer stem cell function in multiple cancers including TNBC [25–29]. Several studies have shown that STAT3 signaling can influence the epithelial to mesenchymal transition (EMT) program and enhance metastatic ability, through a STAT3-dependent transcriptional network [30–34]. Additionally, STAT3 signaling is also implicated in the tumor microenvironment through association with stromal and immune cell components to favorably influence tumor progression and metastasis [25, 35, 36]. Taken together, numerous studies suggest that both the Wnt- and STAT3 pathways play a critical role in tumor onset and metastasis, implying their therapeutic targeting could help to block tumor progression and metastasis.

Despite the important contribution of the Wnt- and STAT3 signaling in tumor progression and metastasis, it remains unclear whether these pathways function in the same cells or different cells within a given tumor, and how the coordination of these pathways is achieved at the molecular and cellular level during tumor progression. Although much less is known about potential collaborative interactions, recent studies have shown a functional cross-talk between the canonical (or non-canonical) Wnt- and STAT3 signaling pathways in tumor initiation and metastasis [37–39]. In this respect, we investigated the population dynamics derived from the Wnt- and STAT3 signaling pathways in primary tumors and metastases using a lentiviral-based signaling reporter system in conjunction with the basal-like p53-null syngeneic mouse models of TNBC. Herein, we identify distinct subpopulations derived from the Wnt- and/or STAT3 signaling pathways changes during metastatic progression with an increasing overlap observed in populations driven by both signaling pathways in metastatic lesions relative to paired primary tumors. Furthermore, the Wnt- and STAT3 signaling pathways significantly contribute to the progression and maintenance of the lung metastases. In addition, the molecular signature in the lung metastases is highly correlated with immune response signatures, and Foxp3 + Treg cells are significantly enriched in the lung metastatic lesions.

**Results**

**Distinct subpopulations derived from the Wnt- and/or STAT3 signaling pathways exist in the primary tumors of the basal-like p53-null mammary tumor models**

Given the key role of Wnt- and STAT3 signaling pathways in tumor progression and their potential functional cross-talk, we first examined the clonal diversity derived from the Wnt- and/or STAT3 signaling pathways. To this end, we employed a lentiviral fluorescent signaling reporter system in conjunction with a syngeneic, transplantable p53-null mammary tumor model, which allowed us to identify functional signaling pathway-driven populations in both in vivo and ex vivo settings. We performed a co-transduction experiment using lentiviral Wnt- and STAT3 signaling reporters, Wnt-mCherry and STAT3-GFP (Fig. 1a). The Wnt reporter has been widely used and validated in multiple systems including p53-null basal-like mammary tumor models [23, 40, 41]. The STAT3 reporter has been successfully validated and its activity has shown to be positively correlated with the p-STAT3 status in human breast cancer cell lines of xenograft models [29]. This signaling reporter system allowed us to identify Wnt- and/or STAT3-active cells by monitoring pathway-dependent transcriptional activities based on expression of the fluorescent reporter proteins, mCherry or eGFP. Briefly, we transplanted the entire co-infected populations into the cleared mammary fat pads of syngeneic recipient mice and analyzed the resulting tumors using flow cytometry. Two basal-like p53-null mammary TNBC models, T1 and T2, were used.

As transduction controls, we utilized lentiviral constructs with constitutive EF1α-driven GFP and -dTomato expression, EFS-GFP and EFS-dTomato, to determine levels of co-infection. Based on co-infection level of these constitutive reporters, we expected there should be a similar co-infection of the lentiviral Wnt- and STAT3 signaling reporters since the same multiplicity of infection (MOI) of these lentiviral vectors was used. Flow cytometric analysis
of tumor cells harboring the lentiviral constitutive reporters revealed that the majority of tumor cells (78 to 95%) were double-positive for GFP and dTomato, confirming the high co-infection rate in both T1 and T2 (Fig. 1b). Interestingly, flow cytometric analysis of tumor cells carrying the lentiviral Wnt- and STAT3 signaling reporters showed a heterogeneous distribution of tumor cells with varying degrees of pathway activities, indicating that heterogeneous populations with respect to Wnt- and STAT3 signaling exist in both T1 and T2 tumors (Fig. 1b). Importantly, these analyses clearly demonstrated that there are distinct subpopulations derived from Wnt- and/or STAT3 signaling pathways, including single-positive (Wnt-active or STAT3-active) cells as well as double-positive (STAT3/Wnt-active) cells (Fig. 1b). Moreover, co-immunofluorescence analysis for Wnt (red)- and STAT3 (green) signaling pathways also confirmed the existence of the distinct subpopulations derived from Wnt- and/or STAT3 signaling pathways (Fig. 1c). These findings suggest that clonal heterogeneity marked by the Wnt- and/or STAT3 signaling pathways exists in the primary tumors of the basal-like p53-null mammary tumors.

**Activation of both Wnt and STAT3 signaling pathways contributes to the lung metastases**

The clonal diversity driven by the Wnt- and/or STAT3 signaling pathways observed in the primary tumor setting prompted our investigation of the involvement of the signaling dynamics and potential heterogeneity during metastatic progression. To evaluate the metastatic lesions in vivo we utilized both primary tumor resection and tail vein injection approaches to model metastasis from the orthotopic site as well as “experimental” metastasis, respectively. While the resection model best recapitulates the clinical scenario, allowing for a multistep metastatic cascade over time, the tail vein approach was used in concert to enable population- and pathway-specific observations with respect to metastatic colonization.
Lung metastases in the T2 model were more frequently observed relative to T1 following resection, thus we primarily utilized T2 for subsequent metastasis studies. Visible lung macrometastases were observed in 8/29 mice after 2 months following resection of primary tumors, suggesting a low metastatic frequency (Fig. 2a), considerably less than other highly aggressive GEM models like MMTV-PyMT [42]. Interestingly, ex vivo imaging analysis revealed that in the majority of metastatic tumor-bearing mice, 5/8 mice exhibited lung metastases with

| Metastasis frequency following resections | STAT3/Wnt | STAT3 | Wnt | Negative |
|-----------------------------------------|-----------|-------|-----|----------|
| Metastatic outgrowth / # of mice        | 5/29 (17%)| 1/29 (3%)| 1/29 (3%)| 1/29 (3%)|

Fig. 2 The Wnt and STAT3 signaling pathways contribute to lung metastases. a Metastasis frequency and pathway activity enriched for the lung metastases after resection of the primary tumors. For the resection experiments, we transplanted the entire tumor cell population co-infected with the lentiviral Wnt- and STAT3 signaling reporters, removed the primary tumors when they reached approximately 0.7–0.8 cm in diameter, and examined the metastatic dissemination to the lung, a common site for TNBC metastasis. Data shown are the number of mice harboring the lung metastases of each pathway activity from two independent experiments (n = 29). The signaling pathway activities were identified by stereomicroscopy. b Representative ex vivo fluorescence image depicting the Wnt (red) and STAT3 (green) signaling activities in the lung metastasis (magnification, ×0.71). Both signaling pathways are activated in the lung metastasis. c Representative ex vivo images of lung metastases driven by the distinct FACS-sorted subpopulations via the tail vein injections. 5 × 10^4 cells were injected into the lateral tail vein and the lung metastases were assessed 2 months after the injections by stereomicroscopy (magnification, ×0.71). STAT3/Wnt (n = 6), STAT3 (n = 4), Wnt (n = 5), and Negative (n = 5) were analyzed. d Metastatic frequency was determined by the number of metastatic nodules based on the stereomicroscopic images. Data shown are the metastatic frequency derived from the FACS-sorted populations from one experiment.
both Wnt- and STAT3 signaling activity (Fig. 2a, b). In addition to surgical resection, we performed experimental tail vein injections to assess lung metastases derived from the distinct FACS-sorted subpopulations. We observed that the intrinsic signaling pathways presented in the primary tumors were maintained during the metastasis (Fig. 2c). While Wnt- and STAT3-only cells maintained their designated pathway activity in the lung, lung metastases derived from Wnt-only cells additionally displayed STAT3 signaling activity after colonization, presumably a result of the lung microenvironment (Fig. 2c). Moreover, the populations activated by both Wnt-and STAT3 signaling pathways exhibited a higher metastatic frequency relative to the other populations (Fig. 2d), suggesting that Wnt- and STAT3 signaling pathways significantly contribute to the metastatic progression in the lungs.

**Overlapping populations derived from both Wnt- and STAT3 signaling pathways are significantly enriched in the lung metastases relative to the primary tumors**

To identify cellular characteristics of the metastatic tumors, we compared various histologic features between primary tumors and matched metastases. Histological analysis revealed that lung metastases exhibited a more disorganized cellular structure and irregular expression of keratins of the basal and luminal lineage, marked by Keratin-14 (K14, red) and ~8 (K8, green), respectively, as compared to the primary tumors (Fig. 3a), suggesting a considerable change in cellular organization in the metastatic nodules. Co-immunofluorescence staining for Wnt (red)- and STAT3 (green) signaling pathways confirmed the populations with various levels of Wnt- and/or STAT3 signaling activities in the metastases (Fig. 3a). Intriguingly, overlapping populations driven by both Wnt- and STAT3 signaling pathways were substantially enriched in lung metastases relative to primary tumors (Fig. 3a). This also was confirmed by the quantitative analysis of confocal fluorescence images based on the expression of RFP (Wnt) and GFP (STAT3) (Fig. 3b and Supplementary Fig. 1a–c). Although cells co-expressing both reporters appeared to constitute minor populations within the primary tumors, they became the dominant populations in the metastases, indicating the dramatic change in Wnt and STAT3 signaling pathways in the metastatic setting.

When comparing the fluorescence intensity of RFP- and GFP between the primary and metastatic tumors, we observed a considerable increase in STAT3 signaling activity in the lung metastases relative to the primary tumors, but no significant change in Wnt signaling activity (Fig. 3c and Supplementary Fig. 2a, b). Moreover, STAT3 signaling activity was preferentially elevated at the leading edge of the metastatic nodule and interface with the surrounding lung tissue as compared to the center (Fig. 3d), suggesting an important spatial role of STAT3 signaling in the lung metastases, possibly through the functional and physical interaction with cellular components in the lung. Collectively, our findings demonstrate that the cellular composition derived from Wnt- and/or STAT3 pathways are altered during metastatic progression, with an increased proportion of the overlapping populations present in the lung metastases, implying there may be a selective advantage of co-expression of both signaling pathways.

**Inhibition of Wnt- and STAT3 signaling pathways decreased the metastatic outgrowth in already-established lung metastases**

Since the overlapping populations driven by both Wnt- and STAT3 pathways are enriched in the lung metastases with increased activity of both signaling pathways, we examined if inhibition of Wnt- and STAT3 pathways was able to inhibit metastatic progression, especially in already-established lung metastases. To address this question, we performed tail vein injections of the double-positive Wnt/STAT3 overlapping populations (50,000 cells) into the mice and allowed them to develop the lung metastases for 1 month (Fig. 4a). The mice then were randomized \((n = 9\) per group) and treated with vehicle or C188-9 (50 mg/kg)/LGK974 (6 mg/kg) for 2 weeks (Fig. 4a). C188-9 is a potent small-molecule that targets the Src-homology (SH) 2 domain of STAT3 and inhibited tumor growth of several cancer models, including breast cancer [43–45]. LGK974 is a specific PORCN inhibitor that targets Porcupine, a Wnt-specific acyltransferase, inhibits Wnt pathway in vitro and in vivo, and induces tumor regression in a Wnt-driven murine tumor model [46, 47]. The mice treated with the C188-9 and LGK974 showed decreased expression of both GFP and RFP expression in the lung metastases, indicating an efficient reduction of the activity of both Wnt- and STAT3 pathways in vivo (Fig. 4b, c). Additionally, the combinatorial treatment was well-tolerated without significant body weight loss during the course of the treatment (Supplementary Fig. 3). Notably, the C188-9/LGK974-treated group showed a significant reduction in the number of metastatic lesions as compared to the vehicle-treated group (Fig. 4d, e), suggesting that the inhibition of the Wnt- and STAT3 pathways can reduce the metastatic burden in already-established lung metastases. These findings further suggest that the activation of Wnt- and STAT3 pathways is critical for the progression and maintenance of the lung metastases, implying that blocking Wnt- and STAT3 pathways could be a potential therapeutic option for metastatic breast cancer.
Immune response-related signatures are highly correlated with the molecular signatures in the metastatic tumors

The differences between primary tumors and matched metastases identified by reporter-based approaches led us to further investigate global gene expression programs that could more comprehensively distinguish primary and matched metastases. RNA sequencing analysis from resected primary tumors \((n = 3)\) and matched metastases \((n = 3)\) identified 818 transcripts differentially expressed \((p < 0.01, t\)-test, fold change > 1.4), the majority of which were upregulated in the lung metastases as compared to the primary tumors (Fig. 5a, left). Principal component analysis (PCA) revealed that the variation in gene expression patterns between the paired primary (gray circle) and metastatic tumors (red circle) are distinct (Fig. 5c). Gene ontology (GO) enrichment analysis of upregulated genes demonstrated that genes categorized in immune response and immune cell activation were significantly enriched in the lung metastases (Fig. 5b, upper plot), suggesting a strong association of immune response signatures within the lung metastases and possible enrichment of cellular components of immune system. Moreover, a supervised analysis derived from the significant modules \([48, 49]\) after removing normal lung signatures also identified the immune

---

**Fig. 3** The cellular composition derived from the Wnt- and/or STAT3 signaling pathways is significantly changed during the metastatic progression. **a** Histological comparison between the primary and lung metastases. Representative images of Hematoxylin and Eosin (H&E) and co-immunofluorescence staining for the K8 (luminal, green) and K14 (basal, red) illustrating the changes in the cellular organization during the metastasis. Lung metastases displayed an increased proportion of the overlapping populations derived from both the Wnt- (red) and STAT3 (green) signaling reporters as compared to the primary tumors. Scale 100 μm (H&E) and 50 μm (immunostaining). **b** Representative quantitative analysis of the heterogeneous populations in the primary and lung metastases based on the RFP- and GFP intensity using the confocal images. Primary tumors \((n = 5, 36\) images) and lung metastases \((n = 5, 49\) images) were analyzed. One-way ANOVA test. The numbers indicate the percentage of double-positive cells based on a threshold of 25 for RFP and 40 for GFP. Blinded analysis was performed during quantification. **c** Representative quantitative comparison analysis of the GFP (STAT3)- and RFP (Wnt) intensity between the primary and metastatic tumors based on the confocal images. Box plots showing the distribution of the GFP- and RFP intensity. In the box plots, the red horizontal lines indicate the median value, and the notches define the 95% confidence interval of the median. Primary tumors \((n = 5, 36\) images) and lung metastases \((n = 5, 49\) images) were analyzed. One-way ANOVA test. Blinded analysis was performed during quantification. The STAT3 signaling pathway is highly enriched in the lung metastases relative to the primary tumors (mean value in primary = 51.6, mean value in lung mets = 67.2), while the Wnt signaling pathway is not significantly changed (mean value in primary = 38, mean value in lung mets = 44.8). **d** Representative co-immunofluorescence staining image for the Wnt (red) and STAT3 (green) signaling pathways revealed that the STAT3 signaling activity is mainly elevated at the leading edge of metastatic tumors. Scale 50 μm
The inhibition of STAT3- and Wnt pathways significantly reduces the metastatic burden in already-established lung metastases. **a** Schematic treatment strategy. FACS-sorted overlapping populations (50,000 cells) were injected via tail veins. DP (Double-Positive for Wnt and STAT3) cells indicate the overlapping populations. The mice were randomized \( (n = 9 \text{ per group}) \) and treated with vehicles and C188-9/LGK974 for 2 weeks (5 days on and 2 days off). The vehicles (60% Labrasol/40% PEG400, 0.5% Methylcellulose/0.5% Tween 80) and C188-9 (50 mg/kg)/LGK974 (6 mg/kg) were given orally. **b** Representative ex vivo fluorescence image depicting the Wnt (red) and STAT3 (green) signaling activities in the lung metastasis (magnification, ×0.71) after C188-9/LGK974 treatment. Metastatic lesions are indicated by red arrows. **c** Quantitative comparison of the GFP (STAT3)- and RFP (Wnt) intensity between the vehicle- and C188-9/LGK974-treated groups based on the confocal images. The fluorescent intensity of the GFP and RFP is substantially reduced by the treatment of C188-9/LGK974. Vehicle group \( (n = 7, 36 \text{ images}) \) and C188-9/LGK974 group \( (n = 4, 24 \text{ images}) \) were analyzed. One-way ANOVA test \( (p = 5e-191 \text{ for GFP and } p = 0 \text{ for RFP}) \). **d** Metastatic frequency after treatment of C188-9/LGK974. The number of metastatic nodules was determined by the stereoscopic images and H&E staining. The C188-9/LGK-treated group \( (n = 9) \) exhibits a lower metastatic frequency relative to the vehicle-treated group \( (n = 9) \). Data shown are the metastasis frequency from one independent experiment. **e** Quantitative analysis of the number of the metastatic nodules in the lung metastases of the vehicle- and C188-9/LGK974-treated groups. Data are shown as the mean ± s.e.m. \( (n = 9 \text{ per group}) \). Unpaired \( t \)-test \( (p = 0.04) \).
modules enriched for in the lung metastases, including modules related to the B cell, T cell, NK cell, and macrophage functions (Fig. 5e and Supplementary Table 1). For instance, Foxp3, Ctra1, Ido1, Cd274, Pdcd1, Tgfβ1, Ccr4, Ccr5, Ccr6, Ccl22, Ccl17, Cxcl12, CD45, Cx3, genes were upregulated in the metastatic tumors compared with the primary tumors (Fig. 5f and Supplementary Fig. 4), indicating a potential enrichment of immune cells in the lung metastases. Consistent with the previous finding that spontaneous lung metastases of PDX models exhibited a more differentiated and less proliferative phenotype [50], the supervised analysis identified upregulated luminal progenitor signatures and downregulated proliferation-related signatures in the lung metastases, supporting the idea that a more differentiated basal-like phenotype in the lung metastases is being selected (Fig. 5e). Furthermore, supervised analysis showed that the STAT3- or Wnt-dependent signatures from human basal-like breast cancers were strongly correlated with the gene signatures enriched for in the metastatic tumors relative to the primary tumors (Fig. 5g), suggesting that the STAT3- and Wnt pathways may play an important role in metastatic progression of human breast cancer, possibly through physical and functional interactions with immune compartments.

Gene expression patterns were also derived from the experimental lung metastases originating from the distinct
Molecular features in the lung metastases are highly associated with the immune response-related gene signatures in the basal-like p53-null mammary tumor model. a Heat maps showing differentially expressed genes comparing the primary vs. matched metastases (left, n = 3) or the primary vs. distinct subpopulation-driven metastases (right, n = 4) in the T2 (p < 0.01 by t-test, fold change > 1.4, using log-transformed data). Bright yellow/blue denotes > 2-fold change in expression from primary group. b Gene ontology analysis of upregulated genes in the metastases revealing the enrichment of immune response- and immune cell activation signatures in the resection model (upper graph). The genes involved in immune response as well as cell death program are enriched across all distinct subpopulation-driven metastases (lower graph). c PCA illustrating the variations in gene expression patterns of individual samples. Primary tumor (black dots, n = 3), matched metastases from resections model (red dots, n = 3), and distinct subpopulations-driven metastases via tail vein model (green dots, n = 4). The top 2000 most variable genes were used in making the plot, with the expression values median centered across sample profiles. d Gene ontology enrichment analysis of upregulated genes in the Wnt-active and STAT3/Wnt-active cell-driven metastases. e Supervised cluster analysis of the differentially expressed modules selected by Supervised Analysis with an estimated FDR (false discovery rate) of 0% and a fold change of at least 1.5x. A total of 129 significant upregulated and 37 downregulated modules were selected and some of them are highlighted in the supervised cluster analysis. f Supervised list of genes differentially expressed derived from Supervised Analysis including a large number of cytokines and receptors that implicated in immune function. g STAT3- and Wnt-dependent gene signatures in human breast cancer. Box plot illustrating the gene signature scores between primary and metastatic tumors of STAT3-associated gene signature specific to basal-like breast tumors and Wnt-associated lung metastasis signature of breast cancer. Both signatures are significantly upregulated in metastasis compared with primary tumors by Supervised Analysis (FDR 0%). Comparisons between two groups were performed by unpaired t-test (two-tailed). Statistically significant values are highlighted in red. Box plot displays the median value on each bar, showing the lower and upper quartile range of the data and data outliers. The whiskers represent the interquartile range. Each dot represents the value of a single sample.

FACS-sorted subpopulations, namely double-negative, Wnt-active, STAT3-active, and STAT3/Wnt-active cells via tail vein injection. RNA sequencing analysis from the tail vein injection (n = 4, lung metastases derived from the distinct FACS-sorted subpopulations) revealed that 408 transcripts were differentially regulated across distinct subpopulations-driven metastases as compared to the primary tumors (Fig. 5a, right). Gene ontology (GO) enrichment analysis of upregulated genes revealed the enrichment of genes involved in immune response as well as cell death in the distinct subpopulation-driven metastases (Fig. 5b, lower plot). Moreover, PCA demonstrated that variations in gene expression were less well correlated among the distinct subpopulation-driven metastases (green dots) (Fig. 5c). Intriguingly, the Wnt-active and STAT3/Wnt-active cell-driven metastases (blue circle) were closely clustered with the matched metastases from the resection model by PCA (Fig. 5c). Notably, gene functional annotation enrichment analysis of these metastases compared to the primary tumors revealed the enrichment of similar immune response signatures that were found in the matched metastasis (Fig. 5d), suggesting that the metastases driven by the Wnt-active and STAT3/Wnt-active cells possess the similar gene expression patterns with the matched metastases from the resection model. Collectively, these findings imply that the overlapping populations derived from the Wnt- and STAT3 signaling pathways enriched within the lung metastases may play a critical role in immune response in the lungs.

Increased infiltration of FoxP3+ Treg cells is mainly associated with lung metastases

Given the enrichment of immune response signatures in the metastatic site, we next examined the existence of the immune cells in the lung metastases. Consistent with the gene signatures enriched for in the lung metastases, immunohistochemistry analysis revealed that CD45+ immune cells were significantly enriched in the lung metastatic lesions (Fig. 6a). A number of immune cells, including FoxP3+ Treg cells, CD8+ T cells, and F4/80+ cells (macrophages) were preferentially enriched in the lung metastatic lesions relative to the primary tumors (Fig. 6b and Supplementary Fig. 5a). The finding of the enrichment of macrophages in the lung metastases also support the previous findings that M2-like macrophages are enriched in various metastatic sites and plays an important role for metastatic progression in human breast cancer [51–53]. However, S100A8+ cells (neutrophils) were detected at similar levels in both the primary and metastatic lesions (Supplementary Fig. 5a). These results were corroborated by quantitative comparison analysis of IHC images (Fig. 6c). Particularly, IHC analysis revealed that FoxP3+ Treg cells were mainly enriched in the lung metastases, but not in the primary tumors (Fig. 6b and Supplementary Fig. 5a), and were not detectable in the normal mammary glands and lung tissues (Supplementary Fig. 5b). Moreover, re-transplantation of the lung metastases enriched for both Wnt- and STAT3 pathways into the mammary fat pads gave rise to tumors with both Wnt- and STAT3 activities as well as increased Treg cells (Supplementary Fig. 6a, b), suggesting a strong positive correlation between the overlapping populations and Treg recruitment regardless of their location. Furthermore, inhibition of Wnt- and STAT3 pathways significantly reduced the number of FoxP3+ Treg cells and macrophages (F4/80+ cells), demonstrating the metastasis-specific recruitment of Treg cells and macrophages, possibly due to the presence of the Wnt/STAT3-double-positive overlapping populations (Fig. 4a and Supplementary Fig. 7). Additionally, co-immunofluorescence staining for the FoxP3 and metastatic tumors driven by both
the Wnt- and STAT3 signaling pathways revealed the cellular distribution of the Foxp3 + Treg cells in the lung metastases, and demonstrated that Foxp3 + Treg cells are located in intra- and peritumoural sites of the lung metastases (Fig. 6d). These findings suggest that Foxp3 + Treg cells may play an important role in metastatic progression through functional and physical interactions with the metastatic tumor cells or other immune cells in the lungs.

Discussion

Intratumoral heterogeneity within a primary tumor is significantly associated with tumor progression and poor clinical outcomes. In particular, the heterogeneous nature of the primary tumor tends to be reflected in the behavior of its corresponding metastasis, which presents a considerable challenge in a clinical setting. However, it is largely unknown how clonal dynamics in the primary tumors influence the development of an invasive phenotype and disease progression throughout the metastatic cascade. In this study, we demonstrated clonal organization and dynamics driven by Wnt- and/or STAT3 signaling pathways in primary tumors and metastases of the basal-like p53-null mouse mammary tumor models. We successfully identified distinct subpopulations driven by Wnt- and/or STAT3 signaling pathways within the primary tumors; negative, Wnt-active, STAT3-active, and STAT3/Wnt-active cells (Fig. 1b, c). Tumor cells co-infected with two signaling reporters exhibited various levels of Wnt- and/or STAT3 signaling activities, suggesting the existence of heterogeneous populations. It is possible that the random

**Fig. 6** Immune cell components, particularly Foxp3 + Treg cells, are highly enriched in the metastatic lesions in the basal-like p53 null mammary tumor model. a Representative immunohistochemical analysis in the lung metastases. H&E and IHC with CD45 antibody. Scale 100 μm. b Representative comparison analysis of IHC for Foxp3 + Treg cells in the matched primary and metastatic tumor. Foxp3 + Treg cells are enriched in the lung metastases relative to the primary tumors. Scale 100 μm. c Quantitative measurement of Foxp3 +, CD8 +, F4/80 +, and S100A8 + cells in IHC images. For quantitative measurements, immunohistochemical staining images were scanned by Aperio ScanScope (Leica Biosystems, Buffalo Grove, IL) and processed using a Aperio ImageScope software. Nuclear v9 algorithm was applied for analysis. Data are shown as the mean ± s.e.m. (n = 4 per group) from two independent experiments. Unpaired t-test. n.s represents not significant. d Representative co-immunofluorescent staining images for the Foxp3 (red, upper panel)/STAT3 (green, upper panel) or Foxp3 (green, lower panel)/Wnt (red, lower panel) illustrating the cellular distribution of the Foxp3 + Treg cells in the lung metastases. GFP + (upper panel) or RFP + (lower panel) cells representing the metastatic tumor cells where the STAT3- and/or Wnt signaling is activated, respectively. Scale 50 μm
integration of lentiviral signaling reporters into tumor cells could potentially affect the differential Wnt and STAT3 signaling activities based on the degree of integration rather than amplitude of actual signaling activity. Nonetheless, we note that the majority of tumor cells were co-infected by the Wnt- and STAT3 signaling reporters based on the parallel co-transduction experiments with constitutive reporters (Fig. 1b).

Metastases can be derived from the rare or minor sub-populations within the primary tumors [8, 54, 55]. However, the clonal population dynamics driving metastasis are not fully understood. In our study, we demonstrated the clonal dynamics during the metastases using a resection approach, which enabled us to evaluate the metastases derived from the divergent clones in the primary sites. The quantitative analysis of immunofluorescence images clearly showed that the cellular composition of the distinct sub-populations derived from the Wnt- and/or STAT3 signaling pathways is changed within the metastasis, as evidenced by increased overlapping Wnt/STAT3-active populations (Fig. 3a, b and Supplementary Fig. 1). In addition, activation of STAT3 signaling is further increased in metastases, preferentially at the lesion edge/lung interface (Fig. 3d). These findings were further supported by Supervised Gene Expression Analysis, which showed that the STAT3- or Wnt-dependent signatures of human basal-like breast cancers were strongly correlated with the gene signatures enriched for in the metastatic tumors relative to the primary tumors (Fig. 5g). Moreover, the overlapping populations exhibited a higher metastatic potential in the lungs as compared to the other populations (Fig. 2c, d), supporting the possibility that metastatic colonization can occur by expansion of the metastatic-competent cells, possibly Wnt/STAT3-active cells, residing within the primary tumors. Alternatively, differences in the lung microenvironment may stimulate and select for a more metastatic-competent state of disseminated tumor cells. To distinguish these possibilities, it will be necessary to use a lineage tracing approach in addition to specific pathway reporters to determine the cell of origin of the metastases.

Although overlapping populations driven by both Wnt-and STAT3 signaling pathways emerge as a dominant population in lung metastases, little is known about the crosstalk between these signaling pathways in cells. In brain and ovarian cancer, it has been reported that STAT3 signaling is interconnected to Wnt/β-catenin signaling through a Gsk3β/Arid1b and miR-92a/DKK1 regulatory axis for tumor initiation and maintenance, respectively [37, 39]. A recent study also demonstrated that Frizzled 2 (Fzd2)-mediated non-canonical Wnt signaling pathway can promote EMT and cellular migration through Fyn and STAT3 signaling [38]. As our lentiviral Wnt reporter system marks tumor cells in which the canonical Wnt signaling pathway is activated through Tcf/Lef-mediated transcriptional activation, it is possible that STAT3 signaling could collaborate with canonical Wnt signaling in the basal-like p53-null mammary tumors. However, we cannot rule out that the STAT3 signaling is involved in both canonical- and non-canonical Wnt signaling pathways. Previous studies support the idea that Wnt and STAT3 pathways might be coordinately regulated in the same cells by the Akt signaling pathway [16, 56–58]. Notably, Akt signaling was shown to play an essential role for survival of metastatic tumors in the lung [59–61]. Therefore, our findings of enriched overlapping populations in metastatic lesions and their significant contribution to metastatic progression (Fig. 2d and Fig. 4d, e), as well as the potential functional linkage between Wnt and STAT3 signaling, strongly suggests the possibility that the Wnt- and STAT3 signaling might collaborate to promote metastasis. Whether they function in a common pathway and regulate a unique set of genes, which are not targets of the individual pathways remains to be determined. Furthermore, given the important contribution of these signaling pathways in metastasis, further studies will be required to determine how the overlapping populations function as a major driver in metastasis.

The key molecular features enriched for the metastatic tumors are mainly associated with the immune response signatures (Fig. 5b–f). Interestingly, genes encoding various cytokines and receptors involved in effector- and regulatory T-cell functions were highly upregulated in the lung metastases (Fig. 5e, f and Supplementary Fig. 4), suggesting the existence of strong immune responses, both stimulatory and suppressive, in the metastatic context. Notably, a number of genes upregulated in the lung metastases were implicated in Treg function (i.e., Foxp3, Idol, Tgfβ1, CCR4, CCR5, CCR6, CCL22, CCL17, CCL5, and CXCL12) [62–65]. Immunostaining analyses showed that the Foxp3 + Treg cells were primarily enriched in the lung metastases and physically associated with the metastatic tumors (Fig. 6b–d and Supplementary Fig. 5a), suggesting a functional crosstalk between these cells. In cancer, Treg cells have shown to promote tumor progression and metastasis by its suppressive role in innate and adaptive anti-tumor immunity [66, 67]. Although the precise role of Tregs in metastasis is still emerging, previous studies using spontaneous metastasis murine models of breast cancer suggest that tumor-infiltrating Tregs are associated with metastatic disease progression and are present in metastatic lesions [68–70]. Moreover, a high density of infiltrating Foxp3 + Tregs in breast tumors are associated with a high risk of relapse and death, especially in ER-positive and basal-like tumors [71–73]. In this respect, our findings that the enrichment of the overlapping Wnt- and STAT3-active cell populations as well as the preferential infiltration of the
Foxp3 + Treg cells in the lung metastases indicate that the Wnt/STAT3-active cells may create immunosuppressive microenvironment through recruiting the Foxp3 + Treg cells to the metastatic sites. A more detailed description of the mechanistic basis by which the overlapping Wnt/STAT3 signaling populations modulate the tumor microenvironment and escape from immune surveillance is clearly warranted.

An important caveat that needs to be considered that previous studies have demonstrated is that the eGFP fluorescent reporter can be immunogenic in some contexts [74, 75]. Accordingly, we examined if the fluorescent reporters-expressing cells may cause an immunologic response in vivo in our Balb/c model. To address the possibility, we performed the tail vein injections with tumor cells without fluorescent reporters (unlabeled) or with constitutive EF1α-driven GFP/dTomato reporters (EFS), monitored the lung metastases, and analyzed the tumor-infiltrating immune cells, such as total T cells (CD3 + cells) and Treg cells (Foxp3 + cells). Surprisingly, the EFS tumor cells exhibited a lower rate of metastatic colonization (metastatic frequency: 3/12) as compared to the the Wnt/STAT3 tumor cells (metastatic frequency: 17/6, Fig. 2d), indicating that the EFS tumor cells are less viable and may elicit more cytotoxic immune responses. These findings also suggest that the Wnt/STAT3 tumor cells are more metastatic and less immunogenic during metastasis, despite a strong expression of GFP- and mCherry. However, the EFS- or Wnt/STAT3-driven lung metastases showed a higher T-cell infiltration relative to the unlabeled cells-driven lung metastases, indicating that the expression of fluorescent proteins may cause a T-cell-mediated immune response (Supplementary Fig. 8). In contrast, the Foxp3 + Treg cells were preferentially enriched in the Wnt/STAT3-driven lung metastases as compared to the unlabeled- and EFS cells-driven lung metastases, further suggesting that the recruitment of Treg cells is correlated with the presence of Wnt/STAT3-double-positive cells (Supplementary Fig. 8). As an independent experiment, the comparative analyses between the paired primary tumors and lung metastases derived from unlabeled tumor cells following resection revealed that the immune signature of the lung metastasis was still evident (data not shown). This immune signature also largely overlapped with the one we observed in the lung metastases where the Wnt- and STAT3 signaling pathways are enriched. Therefore, this observation suggests that the immune signatures identified are unlikely to be only associated with the expression of the fluorescence proteins.

In conclusion, this study demonstrates the existence of the cellular heterogeneity derived from Wnt- and/or STAT3 signaling pathways, as well as the change in population dynamics during tumor progression. A population enriched for both Wnt- and STAT3 signaling pathways was identified as a dominant and metastatic-competent population in the lung metastases. Furthermore, blocking both signaling pathways efficiently reduced the metastatic burden, supporting an idea that pharmacological inhibition of both pathways may be an important option for management of at least some subsets of basal-like metastatic breast cancer. Lastly, the enrichment of immune response-related gene signatures as well as Foxp3 + Treg cells in the lung metastases illustrates the important functional and physical communication between tumor cells and the immune microenvironment.

Materials and methods

Animals studies

For p53-null mammary tumor model mice were maintained in accordance with the rules of the Guide for the Care and Use of Laboratory Animals of the NIH. Animal studies were performed according to guidelines of our institutional IACUC protocol (AN-504). Wild-type Balb/c female mice (3–4 weeks of age for tumor transplantation and 5–6 weeks for tail vein injection) were purchased from ENVIGO (Houston, TX, USA). The T1 and T2 tumors were previously generated and characterized as described [76–78]. Normal mammary gland and normal lung tissue were obtained from wild-type Balb/c and FVB female mice (6–12 weeks). Animal procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at University of North Carolina.

Single-cell preparation of p53-null mammary tumors

p53-null mammary tumors were minced into small pieces using the VIBRATOME and digested with DMEM/F12 containing 1 mg/ml Collagenase A (Roche) for 2 h at 37 °C. Single-cell preparation was performed as described [23].

Lentiviral plasmids and lentiviral transduction

The lentiviral Wnt-mCherry reporter plasmid was purchased from Addgene (7TC #24315, Cambridge, MA, USA). The lentiviral STAT3-GFP and EFS-GFP were generated and validated as described [29]. The lentiviral EFS-dTomato reporter plasmid was generated by replacing the GFP (EFS-GFP) with the dTomato. For lentiviral transduction, single cells (100,000 cells/well) were plated into 24-well ultralow attachment plates in 0.5 ml of PMEC (Primary Mammary...
Epithelial Cell) media (DMEM/F12 supplemented with 5% fetal bovine serum, 5 µg/ml insulin, 10 ng/ml mouse EGF, and AA) and infected with retroviruses harboring Wnt-mCherry and STAT3-GFP (or EFS-GFP and EFS-dTomato) at MOIs of 30, respectively, for ~16 h.

Fluorescence-activated cell sorting and analysis

Tumor cell preparation for FACS analysis was performed as described [79]. Cells were analyzed and sorted by BD Aria II sorter (BD Biosciences). FACS data analysis was performed using FlowJo (Tree Star, Ashland, OR, USA).

Immunostaining analysis

For immunohistochemical staining, paraffin-embedded and 10% neutral buffered formalin-fixed tumor tissues were processed according to Immunohistochemistry General Protocol in the Rosen laboratory resources (https://www.bcm.edu/research/labs/jeffrey-rosen/protocols). Tissue sections were stained with the antibodies against CD45 (1:100; 70-0451; TONBO biosciences, San Diego, CA, USA), Foxp3 (1:100; 14–5773; ThermoFisher Scientific), S100A8 (1:800; MAB3059, R&D Systems, Minneapolis, MN, USA), CD3 (1:400, A0452, Dako), CD8 (1:800, 14–0808–82, ThermoFisher Scientific), F4/80 (1:800, 70076, Cell Signalling). For co-immunofluorescence staining, tumor sections were processed according to Immunofluorescence General Protocol in the Rosen laboratory resources. Tissue sections were incubated with the antibodies against against K8 (1:250; TROMA-1; Developmental Studies Hybridoma Bank, Iowa City, IA, USA), K14 (1:400; PRB-155P; Covance, Princeton, NJ, USA), GFP (1:200; 632381, Clontech, Mountain View, CA, USA), RFP (1:400; 600–400-379; ROCKLAND, Limerick, PA, USA), and Foxp3 (1:200, 14–5773–80, ThermoFisher Scientific). All tissue sections were subjected to Tris-EDTA antigen retrieval for 20 min using microwave heating. Immunofluorescence images were taken by a OLYMPUS BX50 (SPOT Advanced software) or a Nikon A1-R confocal microscope (NIS Elements acquisition software) and analyzed using FIJI Software.

Quantification analysis of confocal fluorescence images

Image segmentation and analysis were performed using custom-made pipelines and scripts in Pipeline Pilot (BioVia) and MatLab (The Mathworks). For each tissue section, cell segmentation was performed by tessellation from the nuclear DAPI signal; nuclear positions were determined from the DAPI channel by grayscale image binarization followed by morphological closing and opening. The resulting objects were used as seeds to conduct tessellation in order to define approximate cell boundaries. Average pixel intensities in the GFP and RFP channels were then measured for each cell. By visual inspection of the images, a value threshold of 40 and 25 was set to call GFP- and RFP positive cells, respectively. Primary tumors (n = 5, 36 images) and lung metastases (n = 5, 49 images) were analyzed. The GFP- and RFP intensity distributions were visualized with scatter plots. Statistical differences of the means of GFP- and RFP intensities between primary and metastatic cells were determined by performing a one-way ANOVA test.

Metastasis and in vivo treatments

For resection experiments, an entire tumor cell population co-infected with the lentiviral Wnt- and STAT3 signaling reporters were engrafted in mammary fat pads of recipient mice. Primary tumors were surgically removed when they reached approximately 0.7–0.8 cm in diameter. Metastatic outgrowths were examined 2 months following resection and reported by the number of mice harboring the lung metastases. Two independent experiments (n = 29). For tail vein injection experiments, the distinct FACS-sorted sub-populations were injected into the lateral tail vein (2 × 10^4 cells for RNA preparation for sequencing and 5 × 10^4 cells for assessment of metastatic frequency. STAT3/Wnt- (n = 6), STAT3- (n = 4), Wnt- (n = 5), and negative cells (n = 5) were analyzed.

For pharmacological inhibition of Wnt and STAT3, FACS-sorted overlapping populations (50,000 cells) were introduced via tail vein injections. One month following the injections, the mice were randomized and treated with vehicles (n = 9) and C188-9/LGK974 (n = 9) for 2 weeks (5 days on and 2 days off). The vehicles (60% Labrasol/40% PEG400, 0.5% Methylcellulose/0.5% Tween 80) and C188-9 (50 mg/kg)/LGK974(6 mg/kg) were administered by oral gavage.

RNA preparation and RNA-sequencing analysis

RNA was purified from tissue chunks of three primary tumors, seven lung metastases, eight normal lung, and twelve normal mammary gland tissues (Supplementary Table 1) following the manufacturer’s protocol (PicoPure RNA Isolation Kit, ThermoFisher Scientific). Gene expression profiles were generated by mRNA-sequencing using an Illumina HiSeq 2000/2500. Briefly, mRNA libraries were made from total RNA using the Illumina TruSeq mRNA sample preparation kit and sequenced on an Illumina HiSeq 2000/2500 using a 2 × 50 bp configuration with an average of 136 million read pairs per sample. Quality-control-passed reads were aligned to the
mouse reference genome (GRCm38) using STAR [80, 81]. The alignment profile was determined by Picard Tools v1.64 (http://broadinstitute.github.io/picard/). Aligned reads were sorted and indexed using SAMtools and translated to transcriptome coordinates then filtered for indels, large inserts, and zero mapping quality using UBU v1.0 (https://github.com/mozack/ubu). Transcript abundance estimates for each sample were performed using SALMON [82]. Raw SALMON read counts for all RNAseq samples were normalized to a fixed upper quartile.

**Gene expression analysis**

**Differential expression analysis**

Differential gene expression was assessed using two-sided t-test and fold change on log-transformed expression values. For Supervised Analysis, RNA-seq normalized gene counts from primary and metastatic tumors (resection model only) were log2 transformed and filtered selecting only those genes present in the 70% of samples. All samples were median centered. Same process was applied to normal mammary gland and normal lung samples in order to obtain a distinctive gene expression signature of normal lung tissue. To identify significantly overexpressed genes in metastatic compared with primary tumors or normal lung compared with normal mammary gland tissue we used two-class Significance Analysis of Microarrays (SAM) [83] with an FDR of 0% using ‘samr’ package in R. Genes commonly overexpressed in normal lung tissue and metastatic tumor were removed from the analysis.

**Gene expression signatures**

We applied a collection of 593 gene expression signatures, representing multiple biological pathways and cell types, to all primary and metastatic tumors. These signatures were obtained from 453 publications partially summarized previously [49, 84] and 41 Gene set enrichment analysis (GSEA) signatures published in the Molecular Signature Database. First, we calculated the gene signature score of each module per tumor and performed Supervised Analysis [83] between metastatic and primary tumors (1). Second, we calculated the gene signature score of each module and performed Supervised Analysis in two more comparisons: (2) Normal lung compared with metastatic lung tissue and (3) normal mammary gland compared with metastatic tissue. The second comparison allowed us to identify the distinctive upregulated signatures of normal lung tissue and, the third one, the distinctive downregulated signatures of mammary gland tissue. Finally, the modules derived from comparison (2) and (3) were removed, respectively, from the first upregulated and downregulated significant list (1), in order to minimize the false-positive modules generated by normal lung or mammary gland tissue contamination. The significant modules between primary tumors and metastasis were correlated-centered and hierarchically clustered with Cluster 3.0 [85] and viewed with Java Treeview version 1.1.6r4 [86, 87]. Some gene signatures were box plotted according to primary and metastatic signature score.

**Statistical analysis**

Unpaired two-tailed t-tests were performed in GraphPad Prism and/or RStudio version 1.1.383 (http://cran.r-project.org) for statistical analysis of two-group comparisons. Error bars represent standard error of mean (± s.e.m) and p < 0.05 was considered statistically significant. The unpaired t-test assumes that the two groups have the same variances. For statistical analyses of expression or the intensities of GFP and RFP between primary tumors and lung metastases or between vehicle- and C188-9/LGK974-treated groups, p-values were determined by a one-way ANOVA test.

**Acknowledgements**

This work was supported by NIH RO1 CA148761 (to JMR and CMP) and by the Susan G. Komen to SGR (PDD17479425). We would like to thank to Dr. Michael T. Lewis for generously providing us with the STAT3-GFP and EFS-GFP reporters. This project was conducted with technical support from the Cytometry and Cell Sorting Core (NIH CA125123 and RR024574) and the expert assistance of Joel M. Sederstrom, the Integrated Microscopy core (NCI CA125123, NIDDKS6338, CPRIT RP150578 and John S. Dunn Gulf Coast Consortium for Chemical Genomics), the Lester and Sue Smith Breast Center Pathology Core, and Human Genome Sequencing Center at Baylor College of Medicine. We thank Yiqun Zhang for technical assistance with the gene expression analyses. We would also like to thank to the IHC laboratory at University of Texas MD Anderson Cancer Center for scanning of IHC images. We specially thank Drs. Michael T. Lewis and Kevin P. Roarty for critically reading and editing the manuscript.

**Compliance with ethical standards**

**Conflict of interest**

CMP is an equity stock holder, consultant, and Board of Director Member, of BioClassifier LLC and GeneCentric Diagnostics. CMP is also listed an inventor on patent applications on the Breast PAM50 and Lung Cancer Subtyping assays. The other authors declare that they have no conflict of interest.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115:423–8.

2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and
patterns of recurrence. Clin Cancer Res: Off J Am Assoc Cancer Res 2007;13:4429–34.
3. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153:17–37.
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–58.
5. Naxerova K, Jain RK. Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin Oncol. 2015;12:258–72.
6. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–91.
7. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109–13.
8. Yachida S, Jones S, Boztic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–7.
9. Celia-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 2016;30:892–908.
10. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA. 2010;107:18115–20.
11. Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015;526:131–5.
12. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16:717–27.
13. Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell. 2013;24:410–21.
14. Jacob LS, Vanharanta S, Obenauf AC, Pirun M, Viale A, Socci ND, et al. Metastatic competence can emerge with selection of preexisting oncogenic alleles without a need of new mutations. Cancer Res. 2015;75:3713–9.
15. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011;481:85–9.
16. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumour-initiating cells. Proc Natl Acad Sci USA. 2010;107:3522–7.
17. Scheipers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science. 2012;337:730–5.
18. Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell. 2013;12:761–73.
19. Schuiltla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152:25–38.
20. Khamrastov AI, Khamrastova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176:2911–20.
21. Geyer FC, Lacroix-Triki M, Savage K, Amedos M, Lambros MB, MacKay A, et al. Beta-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011;24:209–31.
22. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, et al. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidermol Biomark Prev. 2010;19:301–9.
23. Roarty K, Pfefferle AD, Creighton CJ, Perou CM, Rosen JM. Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. Oncogene. 2017;36:5958–68.
24. Toledano M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;13:342–56.
25. Thakur R, Trivedi R, Rastogi N, Singh M, Mishra DP. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep. 2015;5:10194.
26. Moon SH, Kim DK, Cha Y, Jeon I, Song J, Park K.S. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol. 2013;42:921–8.
27. Schroeder A, Herrmann A, Cherryholmes G, Kovolik C, Buettner R, Pal S, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014;74:1227–37.
28. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Sermesche J, Walker SR, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+(+CD24(-)) stem-cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121:2723–35.
29. Wei W, Tweardy DJ, Zhang M, Zhang X, Landau J, Petrovic I, et al. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014;32:2571–82.
30. Chuang CH, Greenside PG, Rogers ZN, Brady JJ, Yang D, Ma RK, et al. Molecular definition of a metastatic lung cancer state reveals a targetable CD109-kinase-Stat axis. Nat Med. 2017;23:291–300.
31. Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124:1853–67.
32. Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ. Identification of a Stat3-dependent transcriptional regulatory network involved in metastatic progression. Cancer Res. 2009;69:6823–30.
33. Kim MJ, Lim J, Yang Y, Lee MS, Lim JS. N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial-mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling. Cancer Lett. 2014;354:33–42.
34. Zhang C, Guo F, Xu G, Ma J, Shao F. STAT3 establishes an immunosuppressive microenvironment during the early stages of breast carcinogenesis to promote tumor growth and metastasis. Cancer Res. 2016;76:1416–28.
35. Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014;14:306–21.
36. Wu J, Keng VW, Patmore DM, Kendall JJ, Patel AV, Jousma E, et al. Insertional mutagenesis identified a STAT3/Anil1/beta-catenin pathway driving neurobloma initiation. Cell Rep. 2016;14:1979–90.
37. Chen MW, Yang ST, Chien MH, Hua KT, Wu CJ, Hsiao SM, et al. The STAT3-miRNA-92-Wnt signaling pathway regulates...
spheroid formation and malignant progression in ovarian cancer. Cancer Res. 2017;77:1955–67.
40. ten Berge D, Kooile W, Fuerer C, Fish M, Erolugu E, Nusse R. Wnt signaling mediates self-organization and axis formation in embryoid bodies. Cell Stem Cell. 2008;3:508–18.
41. Roarty K, Shore AN, Creighton CJ, Rosen JM. Ror2 regulates branching, differentiation, and actin-cytoskeletal dynamics within the mammary epithelium. J Cell Biol. 2015;208:351–66.
42. Fantozzi A, Christoforl G. Mouse models of breast cancer metastasis. Breast Cancer Res. 2006;8:212.
43. Xu X, Kasembeli MM, Jiang X, Tweardy BJ, Tweardy DJ. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS ONE. 2009;4:e4783.
44. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117:5701–9.
45. Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, et al. Multifunctional effects of a small-molecule STAT3 inhibitor on NASH and hepatocellular carcinoma in mice. Clin Cancer Res: Off J Am Assoc Cancer Res. 2017;23:5537–46.
46. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA. 2013;110:20224–9.
47. Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2013;110:12649–54.
48. Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genom. 2011;4:3.
49. Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet. 2014;46:1051–9.
50. Bochkorn J, Prat A, Chang YF, Liu X, Huang S, Shang M, et al. Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res. 2014;74:7406–17.
51. Linde N, Casanova-Abenes M, Sosa MS, Mortha A, Rahman A, Farias E, et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun. 2018;9:21.
52. Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer 2016;2:15025. https://doi.org/10.1038/nbjbcan.2015.25.
53. Zhu L, Jessica L, Onkar S, Joy M, Luedke C, Hall A, et al. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. bioRxiv 2019. https://doi.org/10.1101/525071.
54. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999–1005.
55. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21:751–9.
56. Perry JM, He XC, Sugimura M, Grindley JC, Haug JS, Ding S, et al. Cooperation between both Wnt/β-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev. 2011;25:1928–42.
57. AI-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–8.
58. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23:839–52.
59. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011;20:538–49.
60. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37.
61. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peepoo DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430:1034–9.
62. Wang RF. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol. 2008;69:811–4.
63. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol. 2009;10:689–95.
64. Mougiakakos D, Choudhury A, Lladser K, Joensson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57–117.
65. Xu L, Xu W, Qiu S, Xiong S. Enrichment of CCR6+ Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol. 2010;135:466–75.
66. Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastas- Rev. 2014;33:1025–41.
67. Pereira LMS, Gomes ST, Ishak R, Vallinoto AC. Regulatory T cell and forkhead box protein 3 as modulators of immune homeostasis. Front Immunol. 2017;8:605.
68. Bao PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med. 2013;210:2435–66.
69. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Mendez-Huergo SP, et al. Targeting galectin-1 overrides breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 2013;73:1107–17.
70. Lee-Chang C, Bodogi M, Martin-Montalvo A, Wejska K, Sanghvi M, Moaddel R, et al. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J Immunol. 2013;191:4141–51.
71. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling. Nature. 2011;470:548–53.
72. Bates GJ, Fox SB, Han C, Leek RA, Garcia JF, Harris AL, et al. Recruitment of regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol. 2010;135:466–75.
73. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Mendez-Huergo SP, et al. Targeting galectin-1 overrides breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 2013;73:1107–17.
74. Lee-Chang C, Bodogi M, Martin-Montalvo A, Wejska K, Sanghvi M, Moaddel R, et al. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J Immunol. 2013;191:4141–51.
75. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling. Nature. 2011;470:548–53.
76. Bates GJ, Fox SB, Han C, Leek RA, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24:5373–80.
77. Yan M, Jene N, Byrne D, Millar EK, O’Toole SA, McNeil CM, et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCX4R expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 2011;13:R47.
78. Ansari AM, Ahmed AK, Matsangos AE, Lay F, Born LJ, Marti G, et al. Cellular GFP toxicity and immunogenicity: potential founders in in vivo cell tracking experiments. Stem Cell Rev. 2016;12:553–9.
79. Pollenzi A, Battaglia M, Lombardo A, Amoin A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood. 2004;103:3700–9.
80. Jerry DJ, Kitrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, et al. A mammary-specific model demonstrates the
role of the p53 tumor suppressor gene in tumor development. Oncogene. 2000;19:1052–8.
77. Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, et al. Biological and genetic properties of the p53 null pre-neoplastic mammary epithelium. FASEB J. 2002;16:881–3.
78. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA. 2012;109:2778–83.
79. Chang CH, Zhang M, Rajapakshe K, Coarfa C, Edwards D, Huang S, et al. Mammary stem cells and tumor-initiating cells are more resistant to apoptosis and exhibit increased DNA repair activity in response to DNA damage. Stem Cell Rep. 2015;5:378–91.
80. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
81. Dobin A, Gingeras TR. Mapping RNA-seq Reads with STAR. Curr Protoc Bioinform. 2015;51:11–19.
82. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417–9.
83. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116–21.
84. Fan C, Prat A, Parker J, Liu Y, Carey LA, Troester MA. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 2011;4:3. https://doi.org/10.1186/1755-8794-4-3.
85. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004;20:1453–4.
86. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863–8.
87. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzym. 1999;303:179–205.